{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-116856","form_type":"8-K","ticker":"ERAS","cik":"0001761918","company_name":"Erasca, Inc.","filed_at":"2024-10-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.517208+00:00","generated_at":"2026-05-30T10:35:42.085043+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Erasca reports 40% response rate in NRAS Q61X melanoma cohort from Phase 1b SEACRAFT-1 trial","bullets":["40% (4/10) response rate in efficacy-evaluable NRAS Q61X melanoma patients; 3 confirmed partial responses, 1 unconfirmed.","70% (7/10) of patients remained on treatment as of September 5, 2024 efficacy cutoff.","Mandatory primary rash prophylaxis reduced skin toxicities and drug discontinuation rate vs. prior Novartis trials.","Company expects SEACRAFT-2 Phase 3 randomized dose optimization data readout in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-116856","json":"https://secwatch.observer/filing/0000950170-24-116856.json","markdown":"https://secwatch.observer/filing/0000950170-24-116856.md","text":"https://secwatch.observer/filing/0000950170-24-116856.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1761918/000095017024116856/0000950170-24-116856-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1761918/000095017024116856/eras-20241024.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T10:35:42.085043+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}